Showing results (41-50 of 53) with videos related to
Sort By:
Pageof 6
Gastroenterology|September 1, 2014
Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitisOmoniyi J Adedokun, William J Sandborn, Brian G Feagan, et al.Clinical Pharmacology in Drug Development|April 30, 2016
A phase 1, randomized study to assess the pharmacokinetic comparability of siltuximab derived from two different cell lines in healthy subjectsChao Xu, Chao Han, Joseph Marini, et al.Journal of Clinical Pharmacology|February 6, 2010
Lack of racial differences in the pharmacokinetics of subcutaneous golimumab in healthy Japanese and Caucasian male subjectsJie Ling, Sally Lyn, Zhenhua Xu, et al.Clinical Pharmacokinetics|September 4, 2009
Pharmacokinetics and pharmacodynamics of the erythropoietin Mimetibody construct CNTO 528 in healthy subjectsJuan José Pérez-Ruixo, Wojciech Krzyzanski, Esther Bouman-Thio, et al.Journal of Crohn'S & Colitis|July 22, 2016
Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance StudiesOmoniyi J Adedokun, Zhenhua Xu, Colleen W Marano, et al.Gastroenterology|February 8, 2018
Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's DiseaseOmoniyi J Adedokun, Zhenhua Xu, Christopher Gasink, et al.International Journal of Clinical Pharmacology and Therapeutics|January 30, 2013
Pharmacokinetics and safety of sirukumab following a single subcutaneous administration to healthy Japanese and Caucasian subjectsYanli Zhuang, Zhenhua Xu, Dick E de Vries, et al.Journal of Clinical Pharmacology|July 24, 2013
Utilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2, total CCL2 and carlumab (CNTO 888) concentration time dataGerald J Fetterly, Urvi Aras, Patricia D Meholick, et al.Diabetes|June 28, 2002
Normalization of skeletal muscle glycogen synthesis and glycolysis in rosiglitazone-treated Zucker fatty rats: an in vivo nuclear magnetic resonance studyBeat M Jucker, Thomas R Schaeffer, Robin E Haimbach, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
Absence of adverse effects in cynomolgus macaques treated with CNTO 95, a fully human anti-alphav integrin monoclonal antibody, despite widespread tissue bindingPauline L Martin, Qun Jiao, Joel Cornacoff, et al.Pageof 6